A Bibliometric Analysis of Research on Diabetes and Diabetic Kidney Disease: Emphasizing Biomarkers, International Collaboration, and Thematic Structure
DOI:
https://doi.org/10.12928/admj.v7i2.17797Keywords:
Bibliometric analysis, Biomarker,, Diabetic kidney disease, Research trends,, ScopusAbstract
This bibliometric study analyzes global research trends on diabetic kidney disease (DKD) and biomarkers using data retrieved from the Scopus database, comprising 1,174 publications based on the keywords "Diabetic kidney disease" AND "Biomarker." The study employs VOS viewer software for network visualization and cluster analysis to identify key authors, countries, and thematic research clusters. The results highlight three main clusters: epidemiological and clinical risk factors, biological monitoring of DKD patients, and diagnostic biomarker validation. China and the United States dominate the publication landscape, reflecting substantial investments in biomedical research. Key authors such as Nelson, R.G. and Bjornstad, P. play central roles in advancing this field. This study underscores the multidisciplinary approach required to improve DKD diagnosis and management through biomarker development, with implications for personalized medicine and global collaboration. Further research is needed to develop clinically useful biomarkers that enhance personalized management of diabetic kidney disease
References
Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nature Reviews Nephrology. 2016;12(2):73-81.
International Diabetes Federation (IDF). Type 2 Diabetes.
Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes research and clinical practice. 2018;138:271-281.
Magliano DJ, Boyko EJ. IDF diabetes atlas. Published online 2022.
Tanaka S, Bosi A, Fu EL, et al. Kidney function, kidney function decline, and the risk of abdominal aortic aneurysm: the Stockholm CREAtinine Measurements (SCREAM) project. European Journal of Vascular and Endovascular Surgery. 2025;69(4):601-608.
Niewczas MA, Pavkov ME, Skupien J, et al. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nature medicine. 2019;25(5):805-813.
Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? Indian journal of endocrinology and metabolism. 2016;20(4):546-551. doi:10.4103/2230-8210.183480
Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM. How to conduct a bibliometric analysis: An overview and guidelines. Journal of Business Research. 2021;133:285-296. doi:https://doi.org/10.1016/j.jbusres.2021.04.070
Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The Global Epidemiology of Diabetes and Kidney Disease. Advances in chronic kidney disease. 2018;25(2):121-132. doi:10.1053/j.ackd.2017.10.011
Ferrannini E, Veltkamp SA, Smulders RA, Kadokura T. Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes care. 2013;36(5):1260-1265.
Berhane AM, Weil EJ, Knowler WC, Nelson RG, Hanson RL. Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death. Clinical Journal of the American Society of Nephrology. 2011;6(10):2444-2451.
Ortiz-Martínez M, González-González M, Martagón AJ, Hlavinka V, Willson RC, Rito-Palomares M. Recent developments in biomarkers for diagnosis and screening of type 2 diabetes mellitus. Current diabetes reports. 2022;22(3):95-115.
Bjornstad G, Cuffe-Fuller B, Ukoumunne OC, et al. Healthy Parent Carers: feasibility randomised controlled trial of a peer-led group-based health promotion intervention for parent carers of disabled children. Pilot and Feasibility Studies. 2021;7(1):144. doi:10.1186/s40814-021-00881-5
Bjornstad P, Pyle L, Cherney DZI, et al. Plasma biomarkers improve prediction of diabetic kidney disease in adults with type 1 diabetes over a 12-year follow-up: CACTI study. Nephrology Dialysis Transplantation. 2018;33(7):1189-1196. doi:10.1093/ndt/gfx255
Pavkov ME, Nelson RG, Knowler WC, Cheng Y, Krolewski AS, Niewczas MA. Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney international. 2015;87(4):812-819.
Wang L, Peng W, Zhao Z, et al. Prevalence and treatment of diabetes in China, 2013-2018. Jama. 2021;326(24):2498-2506.
Jakovljevic M, Chang H, Pan J, et al. Successes and challenges of China’s health care reform: a four-decade perspective spanning 1985—2023. Cost Effectiveness and Resource Allocation. 2023;21(1):59. doi:10.1186/s12962-023-00461-9
Li Q, Xie Y, Zuo M, Li F. A comprehensive review of biomarker research in diabetic nephropathy from a global bibliometric and visualization perspective. Medicine. 2024;103(48):e40729. doi:10.1097/MD.0000000000040729
Zou LX, Sun L. Global diabetic kidney disease research from 2000 to 2017: A bibliometric analysis. Medicine. 2019;98(6):e14394. doi:10.1097/MD.0000000000014394
Agur T, Steinmetz T, Goldman S, et al. The impact of metformin on kidney disease progression and mortality in diabetic patients using SGLT2 inhibitors: a real-world cohort study. Cardiovascular Diabetology. 2025;24(1):97.
Rozen-Zvi B, Yahav D, Agur T, et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clinical Microbiology and Infection. 2021;27(8):1173-e1.
Shitrit D, Zingerman B, Shitrit ABG, Shlomi D, Kramer MR. Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. The Oncologist. 2005;10(7):501-507.
Agur T, Ben-Dor N, Goldman S, et al. Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients—a prospective cohort study. Nephrology Dialysis Transplantation. 2021;36(7):1347-1349.
Bielopolski D, Streja E, Steinmetz T, Rozen-Zvi B, Kalantar-Zadeh K. Novel insights in classic versus relative glomerular hyperfiltration and implications on pharmacotherapy. Current Opinion in Nephrology and Hypertension. 2023;32(1):58-66.
Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. Journal of nephropharmacology. 2015;5(1):49.
Hoogeveen EK. The epidemiology of diabetic kidney disease. Kidney and Dialysis. 2022;2(3):433-442.
Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nature reviews Disease primers. 2015;1(1):1-20.
Colhoun HM, Marcovecchio ML. Biomarkers of diabetic kidney disease. Diabetologia. 2018;61(5):996-1011.
Looker HC, Colombo M, Hess S, et al. Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. Kidney international. 2015;88(4):888-896.
Chan JY, Choudhury Y, Tan MH. Predictive molecular biomarkers to guide clinical decision making in kidney cancer: current progress and future challenges. Expert review of molecular diagnostics. 2015;15(5):631-646.
Sadiq IZ, Katsayal BS, Ibrahim B, et al. Data-driven diabetes mellitus prediction and management: a comparative evaluation of decision tree classifier and artificial neural network models along with statistical analysis. Scientific Reports. 2025;15(1):1-16.
Groat D, Corrette K, Grando A, et al. Data-Driven Diabetes Education Guided by a Personalized Report for Patients on Insulin Pump Therapy. ACI open. 2020;4(1):e9-e21. doi:10.1055/s-0039-1701022
Williams DM, Jones H, Stephens JW. Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations. Diabetes, metabolic syndrome and obesity : targets and therapy. 2022;15:281-295. doi:10.2147/DMSO.S331654
Guldemond N. What is meant by ‘integrated personalized diabetes management’: A view into the future and what success should look like. Diabetes, Obesity and Metabolism. 2024;26:14-29.
Stehlé T, Delanaye P. Which is the best glomerular filtration marker: Creatinine, cystatin C or both? European Journal of Clinical Investigation. 2024;54(10):e14278.
Song X, Xiong L, Guo T, et al. Cystatin C is a predictor for long-term, all-cause, and cardiovascular mortality in US adults with metabolic syndrome. The Journal of Clinical Endocrinology & Metabolism. 2024;109(11):2905-2919.
Karger AB, Shlipak MG. Glomerular Filtration Rate (GFR) Estimation with Cystatin C—Past, Present, and Future. Clinical Chemistry. Published online 2025:hvae226.
Wijewickrama ES, Mohamed F, Gawarammana IB, Endre ZH, Buckley NA, Isbister GK. Serum and urinary biomarkers for early detection of acute kidney injury following Hypnale spp. envenoming. PLoS Neglected Tropical Diseases. 2021;15(12). doi:10.1371/journal.pntd.0010011
Gordin E, Gordin D, Viitanen S, et al. Urinary clusterin and cystatin B as biomarkers of tubular injury in dogs following envenomation by the European adder. Research in Veterinary Science. 2021;134:12-18. doi:https://doi.org/10.1016/j.rvsc.2020.11.019
Harjen HJ, Anfinsen KP, Hultman J, et al. Evaluation of Urinary Clusterin and Cystatin B as Biomarkers for Renal Injury in Dogs Envenomated by the European Adder (Vipera berus). Topics in Companion Animal Medicine. 2022;46:100586. doi:https://doi.org/10.1016/j.tcam.2021.100586
Yin C, Wang N. Kidney injury molecule-1 in kidney disease. Renal failure. 2016;38(10):1567-1573.
Gohda T, Kamei N, Koshida T, et al. Circulating kidney injury molecule‐1 as a biomarker of renal parameters in diabetic kidney disease. Journal of diabetes investigation. 2020;11(2):435-440.
Harjen HJ, Nicolaysen T V, Negard T, et al. Serial serum creatinine, SDMA and urinary acute kidney injury biomarker measurements in dogs envenomated by the European adder (Vipera berus). BMC Veterinary Research. 2021;17(1). doi:10.1186/s12917-021-02851-8
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Linda Rosita, barkah Djaka Putrwanto, barkah Djaka Purwanto

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
License and Copyright Agreement
In submitting the manuscript to the journal, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal. Please also carefully read Ahmad Dahlan Medical Journal posting Your Article Policy.
- That it is not under consideration for publication elsewhere.
- That its publication has been approved by all the author(s) and by the responsible authorities - tacitly or explicitly - of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
Copyright
Authors who publish with Ahmad Dahlan Medical Journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.